BridgeBio Pharma, Inc.
Company Stats
- Market Cap
- $12.9B
- as of Sep 30, 2026
- Shares Outstanding
- 195.5M
- Free Float
- 81.2%
Income Statement
- Revenue
- $502.1M
- Operating Income
- -$523.4M
- Net Income
- -$732.9M
- EBITDA
- -$518.0M
- Revenue Growth, 3Y
- 86.3%
- FCF Margin, 3Y Avg
- -2003.6%
- FCF Margin, Worst Year
- -5686.6%
Cash Flow
- Free Cash Flow
- -$447.0M
- FCF Yield
- -3.5%
- Owner FCF Yield
- -4.5%
Balance Sheet
- Cash & Equivalents
- $570.1M
Returns & Capital
- Share Repurchases
- $48.3M
- Buyback Yield, 3Y Avg
- 0.1%
- SBC, 3Y Avg
- $112.5M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $502.1M | -$447.0M | -89.0% |
| FY2024 | $221.9M | -$521.7M | -235.1% |
| FY2023 | $9.3M | -$529.0M | -5686.6% |
| FY2022 | $77.6M | -$424.3M | -546.5% |
| FY2021 | $69.7M | -$511.2M | -733.2% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 13, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back